$HRMY News

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?

Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target

Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit

Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth

Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

Harmony Biosciences (HRMY) Heads To European Narcolepsy Days With New Phase 3 Data

Harmony Biosciences (HRMY) Stock Looks Below Fair Value As Shares Rose 48%

Harmony BioSciences' Wakix Franchise, Pipeline Offer Multiple Value Drivers, Oppenheimer Says

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

Engaging In Options Activity, Kumar Budur Exercises Options Valued At $262K In Harmony Biosciences Hldgs

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript

Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline Progress - What's Changed